Aquatic Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Aquatic Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7,362	Closed	-$358K	–	1438
2025 Q2	$358K	Sell	7,362 -91,972	-93%	-$3.56M	0.01%	902
2025 Q1	$3.38M	Buy	99,334 +51,690	+108%	+$2.19M	0.09%	289
2024 Q4	$1.88M	Sell	47,644 -4,656	-9%	-$220K	0.05%	390
2024 Q3	$2.46M	Buy	52,300 +38,300	+274%	+$1.94M	0.06%	318
2024 Q2	$756K	Sell	14,000 -7,000	-33%	-$405K	0.03%	454
2024 Q1	$1.43M	Sell	21,000 -17,100	-45%	-$1.22M	0.05%	316
2023 Q4	$2.38M	Buy	38,100 +29,200	+328%	+$1.61M	0.06%	292
2023 Q3	$404K	Buy	8,900 +5,700	+178%	+$294K	0.02%	532
2023 Q2	$180K	Sell	3,200 -15,900	-83%	-$902K	0.01%	697
2023 Q1	$864K	Buy	+19,100	New	+$928K	0.05%	303

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Aquatic Capital Management's CRSP Position: Q3 2025 in Review

Aquatic Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 7,362 shares — an estimated $358K sold.

Aquatic Capital Management first reported a position in CRSP in Q1 2023 and held it in 10 quarters. The position peaked at $3.38M in Q1 2025. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Aquatic Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Aquatic Capital Management sold 7,362 CRISPR Therapeutics shares in Q3 2025, an estimated $358K.
Aquatic Capital Management first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 10 quarters.
Aquatic Capital Management's CRISPR Therapeutics position peaked at $3.38M in Q1 2025.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Aquatic Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.